RevOpsis Therapeutics

RevOpsis Therapeutics is a privately held biopharmaceutical company located in Springfield, Illinois. Founded recently, the company currently employs 4 individuals. RevOpsis Therapeutics specializes in developing innovative multispecific antibody therapies. Their proprietary Rev-Mod Platform allows for the assembly of fully human antibody components into functional Multi-Mod biologics, targeting multiple disease pathways simultaneously. Their focus lies in creating treatments for complex diseases, particularly retinal vascular diseases. A key differentiator for RevOpsis Therapeutics is their lead asset, RO-104, a trispecific biologic designed to address retinal vascular diseases like neovascular age-related macular degeneration (nAMD). Unlike existing treatments that primarily target the VEGF-A pathway, RO-104 targets three clinically validated pathways: VEGF-A, VEGF-C, and Ang-2. Preclinical studies demonstrate RO-104's high affinity for all three targets, efficacy in treating choroidal neovascularization, and favorable drug-like properties. For inquiries or further information, interested parties can visit RevOpsis Therapeutics' website at revopsis.com.